Tivic Health Systems (Nasdaq:TIVC) - Aandelenkoers, Nieuws & Analyse

TIVC Overzicht aandelen

Tivic Health Systems Inc. is een gezondheidstechnologiebedrijf dat zich richt op de ontwikkeling en commercialisering van bio-elektronische medicijnen. Meer informatie

TIVC fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Heeft geen betekenisvolle marktkapitalisatie ( $2M )

De winst is de afgelopen 5 jaar met 11.5% per jaar gedaald

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

+ 2 meer risico's

Tivic Health Systems, Inc. Concurrenten

Helius Medical Technologies

NasdaqCM:HSDT

US$1.6m

Venus Concept

NasdaqCM:VERO

US$2.4m

Avinger

NasdaqCM:AVGR

US$2.7m

LogicMark

NasdaqCM:LGMK

US$3.8m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Tivic Health Systems
Historische aandelenkoersen
Huidige aandelenkoers	US$0.26
52 Week Hoogtepunt	US$3.21
52 Week Laag	US$0.22
Bèta	2.41
11 maand verandering	-17.71%
3 maanden verandering	-26.27%
1 Jaar Verandering	-88.91%
33 jaar verandering	-99.93%
5 jaar verandering	n/a
Verandering sinds IPO	-99.95%

Recent nieuws en updates

Recent updates

Tivic Health to acquire nausea treatment products from Reliefband Technologies

Oct 17

We Think Tivic Health Systems (NASDAQ:TIVC) Needs To Drive Business Growth Carefully

Jul 15

Rendement voor aandeelhouders

	TIVC	US Medical Equipment	US Markt
7D	-3.7%	0.9%	2.2%
1Y	-88.9%	21.9%	32.6%

Rendement versus industrie: TIVC presteerde slechter dan de US Medical Equipment -sector, die het afgelopen jaar een rendement van 21.9 % opleverde.

Rendement versus markt: TIVC presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 32.6 % opleverde.

Prijsvolatiliteit

Is TIVC's price volatile compared to industry and market?
TIVC volatility
TIVC Average Weekly Movement	20.6%
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: De aandelenkoers van TIVC is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 21% ) van TIVC is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2016	9	Jennifer Ernst	tivichealth.com

Tivic Health Systems Inc. is een gezondheidstechnologiebedrijf dat zich toelegt op de ontwikkeling en commercialisering van bio-elektronische geneesmiddelen. Het belangrijkste product is ClearUP, een bio-elektronisch geneesmiddel voor de behandeling van sinus- en neusontstekingen. Het bedrijf verkoopt zijn producten rechtstreeks aan de consument via zijn eigen websites en platforms zoals Amazon.com en Walmart.com, evenals aan Amerikaanse online retailers zoals BestBuy en FSAStore en via distributeurs.

Tivic Health Systems, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Tivic Health Systems zich tot de beurswaarde?
TIVC fundamentele statistieken
Marktkapitalisatie	US$2.05m
Inkomsten(TTM)	-US$6.42m
Inkomsten(TTM)	US$957.00k

2.2x

P/S-verhouding

-0.3x

Koers/Winstverhouding

Is TIVC overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
TIVC resultatenrekening (TTM)
Inkomsten	US$957.00k
Kosten van inkomsten	US$711.00k
Brutowinst	US$246.00k
Overige uitgaven	US$6.67m
Inkomsten	-US$6.42m

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.78
Brutomarge	25.71%
Nettowinstmarge	-670.95%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde TIVC op de lange termijn?

Bekijk historische prestaties en vergelijking

TIVC Overzicht aandelen

Risicoanalyse

Tivic Health Systems, Inc. Concurrenten

NasdaqCM:HSDT

US$1.6m

NasdaqCM:VERO

US$2.4m

NasdaqCM:AVGR

US$2.7m

NasdaqCM:LGMK

US$3.8m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$1.48 loss in 3Q 2023)

Enrollment Complete in Tivic Health Optimization Study for Its Non-Invasive Vagus Nerve Stimulation Device

Tivic Health Systems, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Tivic Health Systems, Inc Receives Approval from Institutional Review Board for ncVNS Optimization Study, Readies for Enrollment

Tivic Health® Systems, Inc. Announces Chief Financial Officer Changes

Tivic Health Systems, Inc. has filed a Follow-on Equity Offering in the amount of $20.000001 million.

Recent updates

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$1.48 loss in 3Q 2023)

Enrollment Complete in Tivic Health Optimization Study for Its Non-Invasive Vagus Nerve Stimulation Device

Tivic Health Systems, Inc. to Report Q3, 2024 Results on Nov 14, 2024

Tivic Health Systems, Inc Receives Approval from Institutional Review Board for ncVNS Optimization Study, Readies for Enrollment

Tivic Health® Systems, Inc. Announces Chief Financial Officer Changes

Tivic Health Systems, Inc. has filed a Follow-on Equity Offering in the amount of $20.000001 million.

Second quarter 2024 earnings released: US$0.32 loss per share (vs US$7.16 loss in 2Q 2023)

Tivic Health Systems Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

Tivic Health Systems, Inc., Annual General Meeting, Aug 09, 2024

Tivic Health Systems, Inc. Announces Board of Director Changes

First quarter 2024 earnings released: US$1.01 loss per share (vs US$10.52 loss in 1Q 2023)

Tivic Health Systems, Inc. to Report Q1, 2024 Results on May 15, 2024

Tivic Health Announces Successful Completion of Non-Invasive Vagus Nerve Stimulation Study (Vns); Demonstrates Clinically Effective Biological Changes in the Autonomic, Cardiac, and Central Nervous Systems

Tivic Health Systems, Inc. has filed a Follow-on Equity Offering.

Tivic Health Systems, Inc. has filed a Follow-on Equity Offering.

Full year 2023 earnings released: US$10.40 loss per share (vs US$104 loss in FY 2022)

Tivic Health Announces Completion of Enrollment for Study of Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation

Tivic Health Systems, Inc. Announces Termination of Ryan Sabia as Chief Operating Officer

Tivic Health Systems, Inc. Announces Launch of Second Generation of Tivic ClearUP

Third quarter 2023 earnings released: US$1.48 loss per share (vs US$26.70 loss in 3Q 2022)

Tivic Health Systems, Inc. Regains Compliance With Nasdaq Listing Requirements

Tivic Health Funded Study Begins Enrollment for Novel Non-Invasive Bioelectronic Approach to Vagus Nerve Stimulation

Second quarter 2023 earnings released: US$0.072 loss per share (vs US$0.31 loss in 2Q 2022)

Tivic Health Systems, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Tivic Health Systems, Inc. ClearUP Expands Target Market Offering to Include Individuals Who Are Sleep Deprived, Medication Restricted, and Athletes

First quarter 2023 earnings released: US$0.10 loss per share (vs US$0.23 loss in 1Q 2022)

Tivic Health Systems, Inc. to Report Q1, 2023 Results on May 15, 2023

Tivic Health Launches B2b Portal, Accelerates Healthcare Commercial Sales Expansion

Third quarter 2022 earnings released: US$0.27 loss per share (vs US$0.90 loss in 3Q 2021)

Tivic Health to acquire nausea treatment products from Reliefband Technologies

Tivic Health Systems, Inc. (NasdaqCM:TIVC) entered into an Asset Purchase Agreement to acquire Substantially all of the assets, and certain specified liabilities, of Reliefband Technologies, LLC for $33.5 million.

Second quarter 2022 earnings released: US$0.31 loss per share (vs US$0.49 loss in 2Q 2021)

We Think Tivic Health Systems (NASDAQ:TIVC) Needs To Drive Business Growth Carefully

First quarter 2022 earnings released: US$0.23 loss per share (vs US$0.55 loss in 1Q 2021)

Tivic Health Systems, Inc., Annual General Meeting, Jun 14, 2022

High number of new and inexperienced directors

Tivic Health Systems, Inc. to Report Q4, 2021 Results on Apr 19, 2022

Tivic Health Systems, Inc. Appoints Sanjay Ahuja, as Senior Vice President, Quality Assurance & Regulatory Affairs

Full year 2021 earnings released: US$2.43 loss per share (vs US$1.58 loss in FY 2020)

Tivic Health Systems, Inc. Collaborates With Leading Medical Research Hospital on First Controlled Trial to Extend Tivic’s Bioelectronic Platform